Study guide
5.3 Apheresis Products & Fractionation Products
Specialist in Blood Banking, SBB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB
2 Donors & Collection
2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations
3 Processing, Storage & Component QC
3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control
4 Red Cell & Modified Components
4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes
5 Platelets, Plasma & Cellular Products
5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors
6 Genetics, ABO & Rh
6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii
7 Other Blood Groups & Role in Transfusion
7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence
8 Immunology Foundations
8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement
9 Physiology, Hemostasis & HDFN
9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention
10 Cytopenias & Transplantation
10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation
11 Routine Serologic Testing
11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents
12 Special Serologic Methods
12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid
13 Molecular Platforms & Serologic QA
13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance
14 Indications, Component Therapy & PBM
14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management
15 Adverse Effects of Transfusion
15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases
16 Apheresis & Extracorporeal Circulation
16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation
17 Quality, Safety, Math & Instrumentation
17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation
18 Laboratory Administration (SBB Only)
18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management
5.3 Apheresis Products & Fractionation Products
Key Takeaways Explain This Topic AI
Source plasma is collected by apheresis specifically for further manufacturing into plasma derivatives and is regulated separately from whole blood-derived recovered plasma.
Cohn cold ethanol fractionation separates pooled plasma into components: Fraction I (fibrinogen), Fractions II/III (immunoglobulins), and Fraction V (albumin).
Plasma derivatives include albumin, intravenous immune globulin (IVIG), hyperimmune globulins such as Rho(D) immune globulin, and coagulation factor concentrates, and generally do not require ABO/Rh matching or crossmatching before infusion.
Because derivatives are pooled from thousands of donors, manufacturers apply dedicated viral inactivation steps such as solvent/detergent treatment, pasteurization, or nanofiltration.
The same apheresis platform used for plasma collection also collects single-donor platelets, granulocytes, and hematopoietic progenitor cells by adjusting the separation interface.
Last updated: July 2026
Apheresis as a Collection Platform
Apheresis withdraws whole blood from a donor, anticoagulates it (typically with ACD-A , acid-citrate-dextrose), separates it by centrifugation or, less commonly, membrane filtration, retains the target component, and returns the remaining components to the donor. The same platform collects platelets , transfusable plasma , double red cells , granulocytes , and hematopoietic progenitor cells (HPCs) , simply by adjusting the separation interface and collection parameters. Because citrate anticoagulant binds calcium, donors and patients undergoing apheresis are monitored for citrate toxicity - perioral or extremity tingling and, if untreated, hypocalcemia - typically managed with oral calcium supplementation or by slowing the return rate.
Source Plasma, Recovered Plasma, and Transfusable Apheresis Plasma
Three plasma streams feed different purposes, and the SBB exam expects the distinction to be precise:
Transfusable apheresis plasma (FFP, PF24, etc.) is collected specifically for direct patient transfusion, meets the same infectious disease testing and ABO labeling requirements as whole blood-derived plasma, and follows standard donation intervals.
Source plasma is collected by apheresis specifically as feedstock for fractionation into plasma derivatives , not for direct transfusion, under 21 CFR 630 and 640. Because manufacturing itself adds dedicated pathogen-reduction and purification steps, FDA rules permit source plasma donors to donate up to twice within 7 days, with at least 2 days between donations , a substantially shorter interval than whole blood or transfusable plasma donation allows.
Recovered plasma is the plasma byproduct separated from routine whole blood donations that is not needed for direct transfusion and is instead redirected to fractionation, supplementing the dedicated source plasma supply.
Fractionation: From Pooled Plasma to Derivatives
Large pools of source and recovered plasma are fractionated into purified protein products. The classical method, Cohn cold ethanol fractionation , sequentially precipitates plasma proteins by varying ethanol concentration, temperature, pH, and ionic strength:
- Cohn Fraction Protein Yielded
- Fraction I Fibrinogen
- Fraction II/III Immunoglobulins (basis of IVIG and hyperimmune globulins)
- Fraction IV Alpha and beta globulins
- Fraction V Albumin
Modern manufacturing supplements or replaces steps of the Cohn process with chromatography, but the exam expects familiarity with this classical framework because it explains why a given derivative comes from a specific plasma protein class.
Major Plasma Derivatives and Clinical Use
- Derivative Clinical Use
- Albumin (5%, 25%) Volume expansion, hypoalbuminemia, replacement fluid for therapeutic plasma exchange
- IVIG / SCIG Primary immunodeficiency, immune thrombocytopenia, Kawasaki disease, Guillain-Barre syndrome
- Rho(D) immune globulin (RhIG) Prevention of RhD alloimmunization in RhD-negative patients
- Hepatitis B, rabies, tetanus, varicella-zoster immune globulins Targeted post-exposure prophylaxis
- Factor VIII / Factor IX concentrates Hemophilia A / hemophilia B replacement therapy
- Prothrombin complex concentrate (PCC) Rapid warfarin reversal, factor deficiency
- Antithrombin III concentrate Hereditary antithrombin deficiency, DIC
- Alpha-1 proteinase inhibitor Alpha-1 antitrypsin deficiency-related emphysema
- Regulatory and Safety Distinctions from Cellular Components
Unlike red cells, platelets, or plasma intended for direct transfusion, plasma derivatives generally do not require ABO/Rh matching or pretransfusion compatibility testing , because manufacturing pools, purifies, and dilutes donor antibody to levels that are not clinically significant in routine use. The notable exception the exam likes to test: high-dose IVIG , manufactured from thousands of pooled donations, can retain low but occasionally clinically significant titers of anti-A/anti-B; in non-group-O recipients receiving large or repeated doses, this passively transferred antibody can rarely cause hemolysis.
Because derivatives are pooled from thousands of donors, manufacturers apply dedicated viral inactivation or removal steps beyond donor screening and testing alone:
Solvent/detergent (S/D) treatment disrupts the lipid envelope of enveloped viruses (HIV, hepatitis B, hepatitis C) but has no effect on non-enveloped viruses such as hepatitis A virus or parvovirus B19.
Pasteurization (heat treatment, e.g., albumin heated near 60C for about 10 hours) inactivates most viruses, including some non-enveloped types, through heat denaturation.
Nanofiltration physically removes virus particles by size exclusion regardless of envelope status, complementing chemical or heat methods.
Layering multiple methods compensates for the gap each method leaves on its own, which is why a single derivative product often undergoes more than one inactivation step during manufacturing.
Apheresis-Collected Cellular Products
The same apheresis platform used for plasma exchange and plasma collection also collects single-donor cellular products discussed elsewhere in this chapter and guide: apheresis platelets (Section 5.1), granulocyte concentrates , and hematopoietic progenitor cells (Section 5.4). All rely on the identical principle of density-gradient centrifugation to isolate a target cell layer while returning the remainder of the donor's blood.
Worked Example
A manufacturer needs to remove both enveloped and non-enveloped viral contamination risk from a pooled Factor VIII concentrate. Because solvent/detergent treatment alone would leave non-enveloped viruses such as parvovirus B19 unaddressed, the manufacturer adds a nanofiltration step, which removes virus particles by physical size regardless of envelope status, providing a second, independent layer of viral safety.
Common Traps
Assuming plasma derivatives require the same ABO crossmatch as cellular blood components.
Forgetting that solvent/detergent treatment does not inactivate non-enveloped viruses.
Confusing source plasma's shorter donation interval with whole blood or transfusable plasma donation frequency rules.
Mixing up which Cohn fraction yields albumin versus immunoglobulins.